2008
A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia
Rappaport S, Marcus R, Manos G, McQuade R, Oren D. A Randomized, Double-Blind, Placebo-Controlled Tolerability Study of Intramuscular Aripiprazole in Acutely Agitated Patients With Alzheimer's, Vascular, or Mixed Dementia. Journal Of The American Medical Directors Association 2008, 10: 21-27. PMID: 19111849, DOI: 10.1016/j.jamda.2008.06.006.Peer-Reviewed Original ResearchConceptsAgitation-Calmness Evaluation ScaleIM aripiprazoleIM placeboMixed dementiaIntramuscular aripiprazoleDoses 2 hoursIncidence of oversedationTreatment of agitationHealthcare facilitiesPreliminary efficacy analysisAdverse event reportingNegative Syndrome ScaleLong-term careAcute agitationEfficacy analysisTolerability studyPlaceboPEC scoresAripiprazoleGreater incidenceSyndrome ScaleGreater efficacyPatientsVital signsDementia
2007
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson D, Gilmor M, Yang Y, Moonsammy G, Azzaro A, Oren D, Campbell B. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacology Bulletin 2007, 40: 15-28. PMID: 18007565.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleMajor depressive disorderDepression Rating ScaleHAM-D28Rating ScaleDepressive disorderEfficacy trialsIndividual symptomsTreatment effectsPlacebo-controlled efficacy trialTransdermal systemSelegiline transdermal systemEnd of treatmentHamilton Rating ScaleBeneficial therapeutic effectsMajor monoamine neurotransmittersMonoamine oxidase inhibitorsRandom-effects modelCore depression symptomsGenital symptomsMADRS itemsDrug therapySignificant treatment effectTherapeutic effectSpecific symptoms
2000
Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists. JAMA Psychiatry 2000, 57: 270-276. PMID: 10711913, DOI: 10.1001/archpsyc.57.3.270.Peer-Reviewed Original ResearchMeSH KeywordsAdultAffectBrief Psychiatric Rating ScaleCognition DisordersDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamatesHumansKetamineLamotrigineMaleMental DisordersPerceptual DisordersPlacebosPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSchizophreniaSchizophrenic PsychologyTriazinesVerbal LearningConceptsN-methyl-D-aspartate receptor antagonistNMDA receptor dysfunctionReceptor antagonistNeuropsychiatric effectsGlutamate releaseReceptor dysfunctionSymptom subscalesPlacebo 2 hoursClinician-Administered Dissociative States ScaleAdministration of lamotrigineAdministration of ketamineDouble-blind conditionsNMDA receptor antagonistMood-elevating effectsPositive symptom subscaleBrief Psychiatric RatingNovel therapeutic agentsNegative symptom subscaleHopkins Verbal Learning TestVerbal Learning TestKetamine effectsPsychiatric illnessHealthy subjectsPathophysiologic processesPreclinical studies
1995
The phototherapy light visor: more to it than meets the eye
Teicher M, Glod C, Oren D, Schwartz P, Luetke C, Brown C, Rosenthal N. The phototherapy light visor: more to it than meets the eye. American Journal Of Psychiatry 1995, 152: 1197-1202. PMID: 7625470, DOI: 10.1176/ajp.152.8.1197.Peer-Reviewed Original ResearchConceptsAtypical depressive symptomsLight visorDepressive symptomsHamilton Depression Scale scoresHamilton Depression Rating ScaleBaseline depression scoresDepression Rating ScaleDepression Scale scoresFull clinical responseModerate response rateSeasonal affective disorderDim red lightClinical responseTherapeutic responseTreatment periodEffective treatmentDepression scoresPatientsResponse rateScale scoreAffective disordersRating ScaleBright white lightSignificant differencesSymptoms
1994
A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder
Oren D, Teicher M, Schwartz P, Glod C, Turner E, Ito Y, Sedway J, Rosenthal N, Wehr T. A controlled trial of cyanocobalamin (Vitamin B12) in the treatment of winter seasonal affective disorder. Journal Of Affective Disorders 1994, 32: 197-200. PMID: 7852661, DOI: 10.1016/0165-0327(94)90018-3.Peer-Reviewed Original ResearchConceptsSeasonal affective disorderWinter seasonal affective disorderAffective disordersEffective short-term treatmentWeekly outpatient visitsShort-term treatmentSIGH-SAD scoresPlacebo washoutAntidepressant efficacyOutpatient visitsWashout periodEffective treatmentSame scheduleVitamin B12SAD patientsSignificant differencesTreatmentPatientsWeeksDisordersCyanocobalaminRandom assignmentPlaceboTrialsVisits